Atea Pharmaceuticals Inc
AVIR
查看详细走势图
3.170USD
+0.030+0.96%
收盘 12/22, 16:00（美东）报价延迟15分钟
247.66M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+0.96%
5天
+0.63%
1月
+6.73%
6月
-2.46%
今年开始到现在
-5.37%
1年
-0.63%
查看详细走势图
TradingKey Atea Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2025-12-22操作建议
Atea Pharmaceuticals Inc当前公司基本面数据相对稳定，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名65/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价6.00。中期看，股价处于平稳状态。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Atea Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
3
位分析师
买入
评级
6.000
目标均价
+87.50%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Atea Pharmaceuticals Inc亮点
亮点风险
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. The Company has built a proprietary nucleos(t)ide prodrug platform to develop product candidates to treat single-stranded ribonucleic acid (ssRNA) viruses, which are a prevalent cause of serious viral diseases. The Company’s lead program and focus is on the development of the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an investigational, potent, small-molecule inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A), an essential protein for HCV replication. Bemnifosbuvir is an investigational, orally administered guanosine nucleotide double prodrug which targets the HCV non-structural protein 5B (NS5B) RNA-dependent RNA polymerase and inhibits HCV replication.
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值合理
公司最新PE估值-1.79，处于3年历史合理位
机构加仓
最新机构持股54.23M股，环比增加0.07%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值64.03K
Atea Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Atea Pharmaceuticals Inc简介
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. The Company has built a proprietary nucleos(t)ide prodrug platform to develop product candidates to treat single-stranded ribonucleic acid (ssRNA) viruses, which are a prevalent cause of serious viral diseases. The Company’s lead program and focus is on the development of the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an investigational, potent, small-molecule inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A), an essential protein for HCV replication. Bemnifosbuvir is an investigational, orally administered guanosine nucleotide double prodrug which targets the HCV non-structural protein 5B (NS5B) RNA-dependent RNA polymerase and inhibits HCV replication.
公司代码AVIR
公司Atea Pharmaceuticals Inc
CEOSommadossi (Jean-Pierre)
网址https://ateapharma.com/
常见问题
Atea Pharmaceuticals Inc(AVIR)的当前股价是多少？
Atea Pharmaceuticals Inc(AVIR)的当前股价是 3.170。
Atea Pharmaceuticals Inc的股票代码是什么？
Atea Pharmaceuticals Inc的股票代码是AVIR。
Atea Pharmaceuticals Inc股票的52周最高点是多少？
Atea Pharmaceuticals Inc股票的52周最高点是4.020。
Atea Pharmaceuticals Inc股票的52周最低点是多少？
Atea Pharmaceuticals Inc股票的52周最低点是2.455。
Atea Pharmaceuticals Inc的市值是多少？
Atea Pharmaceuticals Inc的市值是247.66M。
Atea Pharmaceuticals Inc的净利润是多少？
Atea Pharmaceuticals Inc的净利润为-168.38M。
现在Atea Pharmaceuticals Inc(AVIR)的股票是买入、持有还是卖出？
根据分析师评级，Atea Pharmaceuticals Inc(AVIR)的总体评级为买入，目标价格为6.000。
Atea Pharmaceuticals Inc(AVIR)股票的每股收益（EPS TTM）是多少
Atea Pharmaceuticals Inc(AVIR)股票的每股收益（EPS TTM）是-1.770。
相关品种
